FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Mar 10, 2026
vTv Therapeutics Inc. (VTVT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $27.0 million.
Revenue (TTM)
$36.84M
+216600.0% vs year-ago TTM
Net income (TTM)
$-4.76M
+75.7% vs year-ago TTM
Operating cash flow (TTM)
$-16.76M
+23.9% vs year-ago TTM
Free cash flow
$-25.31M
-32.6% vs prior year
EPS
—
Dividend per share
None
Shares outstanding
—
Net cash
$88.93M
FY 2025
Operating margin
-25.1%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VTVT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- High Point, NC
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1641489
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $1.0M | $0 | $2.0M | $4.0M |
| Operating income | -$32.8M | -$24.2M | -$25.5M | -$22.5M | -$21.7M |
| Net income | -$27.0M | -$18.5M | -$20.2M | -$19.2M | -$13.0M |
| Operating cash flow | -$25.3M | -$25.3M | -$19.1M | -$16.0M | -$19.3M |
| Free cash flow | — | -$25.3M | -$19.1M | -$16.0M | — |
| Total assets | $89.9M | $38.3M | $11.0M | $33.2M | $25.5M |
| Total liabilities | $25.5M | $24.0M | $29.6M | $27.4M | $10.3M |
| Stockholders' equity | $64.4M | $12.2M | -$24.7M | -$10.7M | -$9.7M |
| Cash and investments | $88.9M | $36.7M | $9.4M | $17.7M | $22.6M |
| Total debt | $0 | $169,000 | $338,000 | $492,000 | $932,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 6, 2026 | Oct 1, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 29, 2026 | Jun 26, 2026 |
| 8-K |
Current report
Other events
|
May 13, 2026 | May 13, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
All 599 vTv Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.